Company Overview and News

 
Tan Chong on track to turn profitable in FY18F, says CIMB Research

2018-10-08 theedgemarkets
KUALA LUMPUR (Oct 8): CIMB IB Research has an “Add” rating on Tan Chong Motor Holdings Bhd at RM1.57 with a target price of RM2 and said the group is on track to turn profitable (at net profit level) in FY18F, after two years of losses in FY16-17.
4405

 
KLCI seen extending consolidation, firm crude oil price to offer respite

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): The FBM KLCI is expected to continue its consolidation phase and hover below the 1,800-point level but may find some respite from high crude oil prices.
1201 5016 6556 7668 5219 4405 6874 2143 5189

 
KLCI seen extending consolidation, firm crude oil to offer respite

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 26): The FBM KLCI is expected to continue its consolidation phase and hover below the 1,800-point level but may find some respite from high crude oil prices.
1201 5016 6556 7668 5219 4405 6874 2143 5189

 
Sapura Energy, ECM Libra, Hai-O, Velesto, Maxwell, Deleum, Pestech, OpenSys, Sumatec, KUB, V.S. Industry, Ann Joo, Maybulk, Tan Chong Motor and Warisan TC Holdings

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): Based on corporate announcements and news flow today, companies in focus on Wednesday (Sept 26) may include: Sapura Energy Bhd, ECM Libra Financial Group Bhd, Hai-O Enterprise Bhd, Velesto Energy Bhd, Maxwell International Holdings Bhd, Deleum Bhd, Pestech International Bhd, OpenSys (M) Bhd, Sumatec Resources Bhd, KUB Malaysia Bhd, V.S. Industry Bhd, Ann Joo Resources Bhd, Malayan Bulk Carriers Bhd (Maybulk), Tan Chong Motor Holdings Bhd and Warisan TC Holdings Bhd
PBLOF 6874 1295 2143 5189 1201 5016 6556 7668 5219 4405 BSMAF 1818

 
Tan Chong Motor ventures into property investments via stake buy in Warisan TC unit

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): Tan Chong Motor Holdings Bhd (TCMH) is taking up a 24.5% stake in Comit Communication Technologies (M) Sdn Bhd (CCT), which owns a piece of leasehold industrial land in Seksyen 13, Petaling Jaya, Selangor from Warisan TC Holdings Bhd for RM13.24 million cash.
5016 4405 BSMAF 1818

 
PM: Auto industry way out of Sabah’s high cost of living

2018-09-17 malaymail
KOTA KINABALU, Sept 17 — Setting up an automotive industry in Sabah would go a long way in boosting the economy and reducing the cost of living in the state, Prime Minister Tun Dr Mahathir Mohamad said today.
4405

 
KLCI gains 0.61%, crosses 1,800 level as regional sentiment perks up

2018-09-14 theedgemarkets
KUALA LUMPUR (Sept 14): The FBM KLCI rose 0.61% and crossed the 1,800 level at midday break, in line with gains at regional markets, as sentiment received a boost from expectations of fresh US-China negotations.
7084 BATS 4162 5983 0096 7123 5199 CIMDF 1023 3026 1201 3867 6645 4405 HIPEF

 
Who are winners and losers of sales and services tax

2018-08-26 thestar.com.my
Healthy regime: The healthcare industry is one of the biggest beneficiaries under the SST system because consultation fees, medications, usage of medical equipment and ambulance services are exempted.
4405 BATS 4162 2836 BSMAF 1818

 
Tepid growth seen in auto TIV for 2018

2018-08-21 theedgemarkets
KUALA LUMPUR: Shares in DRB-Hicom Bhd rose as much as 9.3% yesterday, as investors reacted positively to news regarding a joint venture (JV) between its 50.1%-owned subsidiary Proton Holdings Bhd and China’s Zhejiang Geely Holding Group that will pave the way for Proton to assemble and market its cars in China.
4588 SMEBF 4405 4197 5983 BSMAF 1818

 
Tan Chong likely to benefit from new model launches

2018-08-16 theedgemarkets
Tan Chong Motor Holdings Bhd (Aug 15, RM1.69) Maintain add with an unchanged target price (TP) of RM2: Tan Chong Motor Holdings Bhd’s second quarter ended June 30, 2018 (2QFY18) earnings before interest, taxes, depreciation and amortisation (Ebitda) rose to RM54 million (as compared with RM48 million in 1QFY18), driven by stronger contributions from the Malaysian operations on the back of favourable foreign exchange (forex) following the appreciation of the ringgit against the US dollar.
4405

 
Tan Chong rises 6.51% on firmer 2Q earnings

2018-08-15 theedgemarkets
KUALA LUMPUR (Aug 15): Shares in Tan Chong Motor Holdings Bhd rose 6.51% this morning after it reported a net profit of RM12.36 million in the second quarter ended June 30 2018 (2QFY18) against a net loss of RM23 million last year, despite a year-on-year decline in car sales, thanks to a favourable sales mix and a stronger ringgit during the quarter.
4405

 
KLCI stages mild rebound, gains seen capped

2018-08-15 theedgemarkets
KUALA LUMPUR (Aug 15): The FBM KLCI staged a mild rebound in early trade this morning, lifted by select blue chips but any gain is seen capped.
HLFBF 5797 7668 6645 0090 4405 1082 5681 3034

7
Trading ideas: AirAsia, KLK, HSL, Pasdec, Scomi Group, Tan Chong

2018-08-15 thestar.com.my
KUALA LUMPUR: AirAsia Bhd , Kuala Lumpur Kepong Bhd , Hock Seng Lee Bhd (HSL), Pasdec Holdings Bhd , Scomi Group Bhd and Tan Chong Motor Holdings Bhd are among the stocks to watch, according to JF Apex Research.
6912 KLKBY 2445 EXPE 6238 4405 7158

 
KLCI seen rising amid global relief rally, support at 1,773

2018-08-15 theedgemarkets
KUALA LUMPUR (Aug 15): The FBM KLCI is seen rising amid some overnight relief rally at most global markets, immediate support at 1,773.
7158 DKSHY 6912 KLKBY 2445 4995 5225 6238 4405 1899 Q0F IHHHF 5908 DKSHF

7
AirAsia, Batu Kawan, KLK, DKSH, Hock Seng Lee, IHH, Nestlé, Pasdec, Scomi, Tan Chong, Versatile Creative and YTL REIT

2018-08-14 theedgemarkets
KUALA LUMPUR (Aug 14): Based on corporate announcements and news flow today, stocks in focus tomorrow may include: AirAsia Group Bhd, Batu Kawan Bhd, Kuala Lumpur Kepong Bhd, DKSH Holdings (M) Bhd, Hock Seng Lee Bhd, IHH Healthcare Bhd, Nestlé (Malaysia) Bhd, Pasdec Holdings Bhd, Scomi Group Bhd, Tan Chong Motor Holdings Bhd, Versatile Creative Bhd and YTL YTL Hospitality REIT.
SLLXF 7158 532843 DKSHY 6912 KLKBY 2445 4995 EXPE 5225 FORTIS 6238 5109 4405 1899 Q0F IHHHF 5908 DKSHF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...